Literature DB >> 20634282

Accelerated spirometric decline in New York City firefighters with α₁-antitrypsin deficiency.

Gisela I Banauch1, Mark Brantly, Gabriel Izbicki, Charles Hall, Alan Shanske, Robert Chavko, Ganesha Santhyadka, Vasilios Christodoulou, Michael D Weiden, David J Prezant.   

Abstract

BACKGROUND: On September 11, 2001, the World Trade Center (WTC) collapse caused massive air pollution, producing variable amounts of lung function reduction in the New York City Fire Department (FDNY) rescue workforce. α₁-Antitrypsin (AAT) deficiency is a risk factor for obstructive airway disease.
METHODS: This prospective, longitudinal cohort study of the first 4 years post-September 11, 2001, investigated the influence of AAT deficiency on adjusted longitudinal spirometric change (FEV₁) in 90 FDNY rescue workers with WTC exposure. Workers with protease inhibitor (Pi) Z heterozygosity were considered moderately AAT deficient. PiS homozygosity or PiS heterozygosity without concomitant PiZ heterozygosity was considered mild deficiency, and PiM homozygosity was considered normal. Alternately, workers had low AAT levels if serum AAT was ≤ 20 μmol/L.
RESULTS: In addition to normal aging-related decline (37 mL/y), significant FEV(1) decline accelerations developed with increasing AAT deficiency severity (110 mL/y for moderate and 32 mL/y for mild) or with low AAT serum levels (49 mL/y). Spirometric rates pre-September 11, 2001, did not show accelerations with AAT deficiency. Among workers with low AAT levels, cough persisted in a significant number of participants at 4 years post-September 11, 2001.
CONCLUSIONS: FDNY rescue workers with AAT deficiency had significant spirometric decline accelerations and persistent airway symptoms during the first 4 years after WTC exposure, representing a novel gene-by-environment interaction. Clinically meaningful decline acceleration occurred even with the mild serum AAT level reductions associated with PiS heterozygosity (without concomitant PiZ heterozygosity).

Entities:  

Mesh:

Year:  2010        PMID: 20634282      PMCID: PMC2972627          DOI: 10.1378/chest.10-0187

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  44 in total

1.  Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes.

Authors:  M L Brantly; J T Wittes; C F Vogelmeier; R C Hubbard; G A Fells; R G Crystal
Journal:  Chest       Date:  1991-09       Impact factor: 9.410

2.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

3.  Age, period, and cohort effects. Influences on differences between cross-sectional and longitudinal pulmonary function results.

Authors:  M D Lebowitz
Journal:  Am J Respir Crit Care Med       Date:  1996-12       Impact factor: 21.405

Review 4.  Interpretation of longitudinal studies. An overview.

Authors:  J P Schouten; I B Tager
Journal:  Am J Respir Crit Care Med       Date:  1996-12       Impact factor: 21.405

5.  Effects of smoking and intermediate alpha 1-antitrypsin deficiency (PiMZ) on lung function.

Authors:  S Eriksson; S E Lindell; R Wiberg
Journal:  Eur J Respir Dis       Date:  1985-10

6.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

7.  Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha 1-antitrypsin deficiency (PiZZ).

Authors:  E Piitulainen; G Tornling; S Eriksson
Journal:  Thorax       Date:  1997-03       Impact factor: 9.139

8.  Bronchial hyperreactivity and other inhalation lung injuries in rescue/recovery workers after the World Trade Center collapse.

Authors:  Gisela I Banauch; Atiya Dhala; Dawn Alleyne; Rakesh Alva; Ganesha Santhyadka; Anatoli Krasko; Michael Weiden; Kerry J Kelly; David J Prezant
Journal:  Crit Care Med       Date:  2005-01       Impact factor: 7.598

Review 9.  Alpha 1-antitrypsin deficiency and the PiMS phenotype: case report and literature review.

Authors:  M F Gourley; G R Gourley; E F Gilbert; G B Odell
Journal:  J Pediatr Gastroenterol Nutr       Date:  1989-01       Impact factor: 2.839

10.  Induced sputum assessment in New York City firefighters exposed to World Trade Center dust.

Authors:  Elizabeth M Fireman; Yehuda Lerman; Eliezer Ganor; Joel Greif; Sharon Fireman-Shoresh; Paul J Lioy; Gisela I Banauch; Michael Weiden; Kerry J Kelly; David J Prezant
Journal:  Environ Health Perspect       Date:  2004-11       Impact factor: 9.031

View more
  20 in total

1.  Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline.

Authors:  Darcy D Marciniuk; P Hernandez; M Balter; J Bourbeau; K R Chapman; G T Ford; J L Lauzon; F Maltais; D E O'Donnell; D Goodridge; C Strange; A J Cave; K Curren; S Muthuri
Journal:  Can Respir J       Date:  2012 Mar-Apr       Impact factor: 2.409

Review 2.  Airway Disease in Rescue/Recovery Workers: Recent Findings from the World Trade Center Collapse.

Authors:  Krystal L Cleven; Mayris P Webber; Rachel Zeig-Owens; Kerry M Hena; David J Prezant
Journal:  Curr Allergy Asthma Rep       Date:  2017-01       Impact factor: 4.806

Review 3.  Biomarkers of patient intrinsic risk for upper and lower airway injury after exposure to the World Trade Center atrocity.

Authors:  Rachel Zeig-Owens; Anna Nolan; Barbara Putman; Ankura Singh; David J Prezant; Michael D Weiden
Journal:  Am J Ind Med       Date:  2016-09       Impact factor: 2.214

Review 4.  Biomarkers of World Trade Center Particulate Matter Exposure: Physiology of Distal Airway and Blood Biomarkers that Predict FEV₁ Decline.

Authors:  Michael D Weiden; Sophia Kwon; Erin Caraher; Kenneth I Berger; Joan Reibman; William N Rom; David J Prezant; Anna Nolan
Journal:  Semin Respir Crit Care Med       Date:  2015-05-29       Impact factor: 3.119

5.  Inflammatory biomarkers predict airflow obstruction after exposure to World Trade Center dust.

Authors:  Anna Nolan; Bushra Naveed; Ashley L Comfort; Natalia Ferrier; Charles B Hall; Sophia Kwon; Kusali J Kasturiarachchi; Hillel W Cohen; Rachel Zeig-Owens; Michelle S Glaser; Mayris P Webber; Thomas K Aldrich; William N Rom; Kerry Kelly; David J Prezant; Michael D Weiden
Journal:  Chest       Date:  2012-08       Impact factor: 9.410

6.  Metabolic syndrome biomarkers predict lung function impairment: a nested case-control study.

Authors:  Bushra Naveed; Michael D Weiden; Sophia Kwon; Edward J Gracely; Ashley L Comfort; Natalia Ferrier; Kusali J Kasturiarachchi; Hillel W Cohen; Thomas K Aldrich; William N Rom; Kerry Kelly; David J Prezant; Anna Nolan
Journal:  Am J Respir Crit Care Med       Date:  2011-11-17       Impact factor: 21.405

Review 7.  Health effects following exposure to dust from the World Trade Center disaster: An update.

Authors:  Matthew J Mears; David M Aslaner; Chad T Barson; Mitchell D Cohen; Matthew W Gorr; Loren E Wold
Journal:  Life Sci       Date:  2021-11-14       Impact factor: 5.037

Review 8.  Why is Disease Penetration so Variable in Alpha-1 Antitrypsin Deficiency? The Contribution of Environmental Factors.

Authors:  Madhu Rangaraju; Alice M Turner
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

9.  SERPINA1 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort.

Authors:  Gian-Andri Thun; Ilaria Ferrarotti; Medea Imboden; Thierry Rochat; Margaret Gerbase; Florian Kronenberg; Pierre-Olivier Bridevaux; Elisabeth Zemp; Michele Zorzetto; Stefania Ottaviani; Erich W Russi; Maurizio Luisetti; Nicole M Probst-Hensch
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

10.  Deficiency of α-1-antitrypsin influences systemic iron homeostasis.

Authors:  Andrew J Ghio; Joleen M Soukup; Judy H Richards; Bernard M Fischer; Judith A Voynow; Donald E Schmechel
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.